A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.
默沙东的肿瘤药物Keytruda ...
刚刚，FDA 结束了为期 1 天的肿瘤药物咨询委员会（ODAC）会议，讨论了 PD-1 抑制剂在临床的适应症及应用情况。会议主要涉及 3 款已上市的 PD-1 抑制剂药物，分别是：默沙东的帕博利珠单抗（pembrolizumab，K ...
▎药明康德内容团队编辑默沙东（MSD）今日宣布，美国FDA已批准其重磅PD-1抑制剂Keytruda（pembrolizumab）与培美曲塞和铂类化疗联合，作为一线疗法治疗不可切除的晚期或转移性恶性胸膜间皮瘤（MPM）成年患者。恶性间皮瘤是一类起源于 ...
BMS和默沙东方面则是主张维持现有的“全人群”适应症的标签。BMS的会议简报提到，不同药物的各项研究的评分方法和截断值存在差异，实施任何截断值都有可能让一部分患者失去获益的机会。
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
Dr. Patel：我是加州大学圣地亚哥分校肿瘤内科学教授Sandip Patel医学博士，担任WCLC ...
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈